Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$0.34
EPS est.
$0.27
EPS surprise
+25.46%
1-day move
+2.42%
Elanco Animal Health reported a better-than-expected EPS for the quarter, which led to a positive stock reaction, rising by 2.42%. However, there was no revenue figure provided, leaving some uncertainty about overall performance. Investors may view the EPS beat as a sign of operational strength, but the lack of revenue data could raise questions about future growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.34 | N/A | +25.46% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Elanco Animal Health Incorporated is a company that focuses on animal health products, providing solutions for pet and livestock health. As part of the health care sector, it plays a crucial role in ensuring the well-being of animals, which is increasingly important as global demand for animal protein rises.
Last quarter
In Q1 2026, Elanco reported an EPS of $0.40, surpassing expectations by 16.28%. The stock reacted positively, gaining 13.88% the following day.
EPS beat streak
6Q
EPS beat rate
88%
Avg EPS surprise
+20.20%
Avg 1-day reaction
+9.05%
Investors are cautiously optimistic ahead of the earnings report, especially given the company's strong history of beating EPS estimates.
Bull case
If Elanco continues its trend of exceeding earnings expectations, it could signal robust demand for its products and strong operational efficiency.
Bear case
Conversely, any signs of slowing revenue growth or failure to meet EPS expectations could lead to a decline in investor confidence and stock price.
The print will turn on these.
Q1
What will be the EPS for Q2-2026?
Given Elanco's strong history of beating EPS estimates, this figure will be crucial for investor sentiment and stock performance.
Q2
How is revenue growth tracking compared to previous quarters?
Revenue growth is essential for assessing the company's market position and future prospects, especially in a competitive industry.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate Elanco's ability to capitalize on increasing pet ownership and livestock health demands, which could drive stronger-than-expected revenue growth.
Supporting evidence
Elanco has consistently beaten EPS estimates, suggesting stronger operational performance than analysts anticipate.
The options market is pricing a move of 9.24%, which is below the historical average realized move, indicating potential undervaluation of volatility.
Recent trends in pet ownership and livestock health indicate a growing market that Elanco is well-positioned to exploit.
Key risk
If revenue growth exceeds expectations, it could challenge the current cautious outlook and lead to a significant upward revision in stock price.
Pre-commit to what would confirm each case.
The core debate this quarter centers around whether Elanco can maintain its growth momentum and profitability in a challenging market.
Bull confirmed if
An EPS of $0.45 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.30 would confirm the bear case, raising concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±9.24%
Historical Avg
±11.0%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±9.2% while ELAN has averaged ±11.0% over the last 8 prints — setup is pricing cheap.
ATM IV
0.5%
30d HV
67.6%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options pricing cheap in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
115.25%
of float
Insider
1.21%
of float
Holders
695
institutions
Top Holders· as of Jun 2026
Dodge & Cox Inc.
67,397,025 sh · $1.5B
13.49%
-2.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Elanco beats expectations, history suggests the stock could rise by around 11.22%, confirming strong demand and operational efficiency.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors digest the details and management commentary.
Miss
A miss could lead to a decline of approximately 3.69%, reflecting disappointment in growth prospects.
The lines on the call that would change the story.
FMR, LLC
56,948,819 sh · $1.3B
11.40%
11.8%
Blackrock Inc.
48,849,973 sh · $1.1B
9.78%
2.6%
Primecap Management Company
45,445,012 sh · $1.0B
9.10%
-0.9%
T. Rowe Price Investment Management, Inc.
28,750,719 sh · $642.9M
5.75%
-17.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.